(2S)-1-(2-{[(2S)-1-acetylpyrrolidin-2-yl]formamido}acetyl)pyrrolidine-2-carboxylic acid trifluoroacetic acid hydrate

• ChemBase编号: 155024
• 分子式: C16H24F3N3O8
• 平均质量: 443.3722696
• 单一同位素质量: 443.1515494
• SMILES: CC(=O)N1CCC[C@H]1C(=O)NCC(=O)N1CCC[C@H]1C(=O)O.C(=O)(C(F)(F)F)O.O
• Canonical SMILES: OC(=O)C(F)(F)F.O=C(N1CCC[C@H]1C(=O)O)CNC(=O)[C@@H]1CCCN1C(=O)C.O
• InChI: InChI=1S/C14H21N3O5.C2HF3O2.H2O/c1-9(18)16-6-2-4-10(16)13(20)15-8-12(19)17-7-3-5-11(17)14(21)22;3-2(4,5)1(6)7;/h10-11H,2-8H2,1H3,(H,15,20)(H,21,22);(H,6,7);1H2/t10-,11-;;/m0../s1
• InChIKey: UCOFOXNKITYGTK-ULEGLUPFSA-N

名称和登记号

名称

• IUPAC标准名: (2S)-1-(2-{[(2S)-1-acetylpyrrolidin-2-yl]formamido}acetyl)pyrrolidine-2-carboxylic acid trifluoroacetic acid hydrate
• IUPAC传统名: (2S)-1-(2-{[(2S)-1-acetylpyrrolidin-2-yl]formamido}acetyl)pyrrolidine-2-carboxylic acid trifluoroacetic acid hydrate
• 别名: 1-Acetyl-L-prolylglycyl-L-proline; Acetyl Pro-Gly-Pro; Acetyl-proline-glycine-proline; N-α-PGP; acPGP; Ac-PGP trifluoroacetate salt hydrate

登记号

• CAS号: 292171-04-1(freebase)
• MDL号: MFCD20134196
• PubChem SID: 162249162
• PubChem CID: 71312058

理论计算性质

• Acid pKa: 3.5801616
• 质子受体: 5
• 质子供体: 2
• LogD (pH = 5.5): -3.7708352
• LogD (pH = 7.4): -5.2062016
• Log P: -1.8563358
• 摩尔折射率: 75.4202 cm^3
• 极化性: 29.383287 Å^3
• 极化表面积: 107.02 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: deionized water: ≥2 mg/mL
• 外观: white to tan powder

安全信息

• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 22
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H302
• 保存温度: -20°C

产品相关信息

• 纯度: ≥98% (HPLC)
• 运输包装: wet ice
• Empirical Formula (Hill Notation): C14H21N3O5 · xC2HF3O2 · yH2O

详细说明

Sigma Aldrich - A2112

Biochem/physiol Actions
N-acetyl Proline-Glycine-Proline (ac-PGP) is a potent and selective neutrophil chemoattractant. It is generated enzymatically from extracellular matrix proteins such as collagen. PGP is generated from native collagen by the action of matrix metalloproteinase-8 (MMP-8) and/or MMP-9, followed by a secondary cleavage by prolyl endopeptidase (PE). N-terminal acetylation of PGP (Ac-PGP) occurs through an unknown mechanism. Both PGP and AcPGP are considered biomarkers and possible therapeutic targets for chronic obstructive pulmonary disease (COPD) and may also be markers for acute pulmonary exacerbation in Cystic Fibrosis.